Health

Alexion, AstraZeneca Rare Disease, will transition to 100% renewable energy for Ireland operations sites in 15-year biomethane gas purchase agreement

Alexion, AstraZeneca Rare Disease has announced a major clean-energy milestone, committing to 100 percent biomethane for its Dublin and Athlone sites through a 15-year partnership with Carbon AMS, marking the first large-scale biomethane adoption by a pharmaceutical company in Ireland.

By Chantal Thurlby-Alexander November 24, 2025 5 min read

Repro Free: DUBLIN, IRELAND – 24 November 2025 – Alexion, AstraZeneca Rare Disease, today announced that it will transition to biomethane to provide 100% of its heating needs at its Dublin and Athlone, Ireland sites, making it the first pharmaceutical company in the country to fully embrace this sustainable energy source to fuel the research, development and manufacturing of medicines. This landmark initiative will be achieved through a fifteen-year partnership with Carbon AMS, a leading biomethane producer and will contribute to the Company’s flagship decarbonisation programme, Ambition Zero Carbon. This agreement is the first large-scale biomethane contract with ‘additionality’ in Ireland, meaning the project will add renewable capacity to Ireland’s national gas grid. Biomethane will be sourced from a new state-of-the-art plant strategically located in Duleek, Co. Meath—approximately 30km from Alexion’s College Park site and 120km from its Athlone operations—and will use grass silage obtained through long-term contracts with local farmers. Construction of the Duleek facility is expected to be completed, and the first supply. Pictured were Phil Doyle, Managing Director, Fund Management, Richard Kennedy, Chief Executive Officer & Co-Founder, Carbon AMS with Darragh O'Brien TD, Minister for Climate, Environment and Energy and Minister for Transport and Shane Doyle, Senior Vice President, Global Operations and Sustainability, Alexion, AstraZeneca Rare Disease. Picture Jason Clarke.

Commitment to landmark biomethane partnership reflects pioneering leadership in sustainable energy transition

DUBLIN, IRELAND – 24 November 2025 – Alexion, AstraZeneca Rare Disease, today announced that it will transition to biomethane to provide 100% of its heating needs at its Dublin and Athlone, Ireland sites, making it the first pharmaceutical company in the country to fully embrace this sustainable energy source to fuel the research, development and manufacturing of medicines. This landmark initiative will be achieved through a fifteen-year partnership with Carbon AMS, a leading biomethane producer and will contribute to the Company’s flagship decarbonisation programme, Ambition Zero Carbon.